Skip to content

Effect of chamomile syrup on acute leukemia

Study of the effect of chamomile syrup oral application in prevention of chemotherapy-induced neutropenia in pediatric ALL patients

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013021612486N1
Enrollment
36
Registered
2017-05-30
Start date
2017-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia (ALL). Acute lymphoblastic leukaemia [ALL]

Interventions

Intervention 1: Daily 2.5 cc chamomile syrup orally for 30 days in the intervention group. Intervention 2: Daily 2.5 cc placebo syrup orally for 30 days in the control group.
Prevention
Daily 2.5 cc chamomile syrup orally for 30 days in the intervention group
Daily 2.5 cc placebo syrup orally for 30 days in the control group

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Pediatric (2-18 years old) ALL B cell patients admitted in Shiraz Amir hospital ; Signing written informed consent; Non-usage of any other herbal therapies. Exclusion Criteria: Sensitivity to chamomile; Refuse to cooperate

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
GCSF consumption. Timepoint: before and after the intervention. Method of measurement: Checking hospital documents.;Absolute Neutrophil Count (ANC). Timepoint: before, during, and after the intervention. Method of measurement: Calculation according to the white blood cell count and neutrophil percentage.

Secondary

MeasureTime frame
Quality of life. Timepoint: before and after the intervention. Method of measurement: Standard questionnaire.;Hospital course duration. Timepoint: after the intervention. Method of measurement: Hospital documents.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBabak Daneshfard

Shiraz University of Medical Sciences

babakdaneshfard@gmail.comdaneshfard@sums.ac.ir+98 71 3234 5145

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026